Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases.
BACKGROUND
Increased serum lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerosis. We previously reported that aspirin reduced Lp(a) production by cultured hepatocytes via the reduction of apolipoprotein(a) [apo(a)] gene transcription.


METHODS
We evaluated both the effect of aspirin treatment (81 mg/day) on serum Lp(a) concentrations and the correlation between the degree of reduction in serum Lp(a) and the type of apo(a) isoform in 70 patients with coronary artery disease or cerebral infarction.


RESULTS
Aspirin lowered serum Lp(a) concentrations to approximately 80% of the baseline values in patients with high Lp(a) concentrations (>300 mg/L). The percentage of decrease in serum Lp(a) was larger in patients with high Lp(a) than in patients with low Lp(a) (<300 mg/L), irrespective of apo(a) isoform size. The decreases in serum Lp(a) in high Lp(a) patients with both the high-molecular-weight and the low-molecular-weight isoforms were positively correlated with the baseline Lp(a) concentrations.


CONCLUSIONS
Because the secretory efficiencies of apo(a) in the same isoform are likely to be similar, the difference in serum Lp(a) concentrations in patients having the same apo(a) isoform depends on the transcriptional activity of the apo(a) gene. These findings suggest that aspirin decreases serum Lp(a) concentrations via a decrease in apo(a) gene transcription more effectively in patients with high transcriptional activity of this gene.
Department of Medicine & Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan. akaike@clin.med.tokushima-u.ac.jp
Masashi
M
Akaike
Hiroyuki
H
Azuma
Ayako
A
Kagawa
Kazuya
K
Matsumoto
Ikuro
I
Hayashi
Katsuya
K
Tamura
Takeshi
T
Nishiuchi
Takahiko
T
Iuchi
Nobuyuki
N
Takamori
Ken-ichi
K
Aihara
Tomonori
T
Yoshida
Yasuhiko
Y
Kanagawa
Toshio
T
Matsumoto
D001161:Arteriosclerosis / Q000097:blood / Q000378:metabolism* / Q000517:prevention & control*; D001241:Aspirin / Q000627:therapeutic use*; D002544:Cerebral Infarction / Q000097:blood / Q000378:metabolism / Q000517:prevention & control; D003327:Coronary Disease / Q000097:blood / Q000378:metabolism / Q000517:prevention & control; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D017270:Lipoprotein(a) / Q000097:blood*; D008297:Male; D008875:Middle Aged; D020033:Protein Isoforms
D000960:Hypolipidemic Agents; D017270:Lipoprotein(a); D020033:Protein Isoforms; D001241:Aspirin